Citation:Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al 2009

Citation

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009 Mar 26;360(13):1310-9 Available from: http://www.ncbi.nlm.nih.gov/pubmed/19297565.

This is a publication of PLCO

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al 2009	For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?	Tracy Tsang	completed
Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al 2009 2	For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?	Suzanne Hughes	completed

Compare quality appraisals for each clinical question

• [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?|]] (compare critical appraisals)
• [[Clinical question:For asymptomatic men without a prostate cancer diagnosis, what PSA testing strategies with or without DRE compared to no PSA testing or other PSA testing strategies reduce prostate cancer specific mortality or the incidence of metastases at diagnosis?|]] (compare critical appraisals)

Cited by

1. Introduction
2. PSA Testing strategies